Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

（原标题：北陆药业(300016.SZ)：获得吡格列酮二甲双胍片《药品注册证书》） 格隆汇12月12日丨北陆药业(300016.SZ)公布，收到国家药品监督管理局核准签发的吡格列酮二甲双胍 片（15mg/500mg）的《药品注册证书》。吡格列酮二甲双胍片（15mg/500mg）的原研企业是武田药品 工业株式会社，2005年8月获美国批准上市。目前，原研厂家的吡格列酮二甲双胍片尚未在中国上市。 本品适用于在饮食控制和运动的基础上，用于目前使用盐酸吡格列酮和盐酸二甲双胍联合治疗的2型糖 尿病患者或单用盐酸二甲双胍治疗后血糖控制不佳的2型糖尿病患者。 ...

北陆药业12月12日公告，公司近日收到国家药品监督管理局核准签发的吡格列酮二甲双胍片 （15mg/500mg）《药品注册证书》。吡格列酮二甲双胍片（15mg/500mg）按照化学药品3类获批，视 同通过仿制药质量和疗效一致性评价，进一步丰富了公司降糖药产品管线，有助于提升公司产品的市场 竞争力。公司将积极开展新产品上市的各项准备工作，并尽快将产品推向市场，但其生产和销售可能会 受到一些不确定性因素的影响。 ...

格隆汇12月12日丨北陆药业(300016.SZ)公布，收到国家药品监督管理局核准签发的吡格列酮二甲双胍 片（15mg/500mg）的《药品注册证书》。吡格列酮二甲双胍片（15mg/500mg）的原研企业是武田药品 工业株式会社，2005年8月获美国批准上市。目前，原研厂家的吡格列酮二甲双胍片尚未在中国上市。 本品适用于在饮食控制和运动的基础上，用于目前使用盐酸吡格列酮和盐酸二甲双胍联合治疗的2型糖 尿病患者或单用盐酸二甲双胍治疗后血糖控制不佳的2型糖尿病患者。 ...

北陆药业（300016）(300016.SZ)公告，公司收到国家药品监督管理局核准签发的吡格列酮二甲双胍片 (15mg/500mg)的《药品注册证书》。本品适用于在饮食控制和运动的基础上，用于目前使用盐酸吡格列 酮和盐酸二甲双胍联合治疗的2型糖尿病患者或单用盐酸二甲双胍治疗后血糖控制不佳的2型糖尿病患 者。 ...

北陆药业公告，近日收到国家药品监督管理局核准签发的吡格列酮二甲双胍片（15mg/500mg）的《药 品注册证书》。该药品适用于在饮食控制和运动的基础上，用于目前使用盐酸吡格列酮和盐酸二甲双胍 联合治疗的2型糖尿病患者或单用盐酸二甲双胍治疗后血糖控制不佳的2型糖尿病患者。根据米内网数据 显示，2024年中国三大终端六大市场吡格列酮二甲双胍片的销售额约为16.74亿元，其中城市公立医院 和县级公立医院销售额为11.83亿元，城市社区中心和乡镇卫生院销售额为1.95亿元，城市实体药店和网 上药店销售额为2.96亿元。 ...

智通财经APP讯，北陆药业(300016.SZ)公告，公司收到国家药品监督管理局核准签发的吡格列酮二甲双 胍片(15mg/500mg)的《药品注册证书》。本品适用于在饮食控制和运动的基础上，用于目前使用盐酸吡 格列酮和盐酸二甲双胍联合治疗的2型糖尿病患者或单用盐酸二甲双胍治疗后血糖控制不佳的2型糖尿病 患者。 ...

股票代码：300016 股票简称：北陆药业 公告编号：2025-120 北京北陆药业股份有限公司 关于获得吡格列酮二甲双胍片《药品注册证书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，北京北陆药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的吡格列酮二甲双胍片（15mg/500mg）的《药品注册证书》。 现将相关情况公告如下： 一、药品的基本情况 药品通用名称：吡格列酮二甲双胍片（15mg/500mg） 上市许可持有人地址：北京市密云区水源西路 3 号 1 主要成份：盐酸吡格列酮、盐酸二甲双胍 剂型：片剂 规格：每片含盐酸吡格列酮 15mg（以 C₁₉H₂₀N₂O₃S 计）和盐酸二甲双胍 500mg 注册分类：化学药品 3 类 药品有效期：18 个月 包装规格：7 片/板，2 板/袋，2 袋/盒 处方药/非处方药：处方药 上市许可持有人名称：北京北陆药业股份有限公司 受理号：CYHS2401078 证书编号：2025S03711 药品注册标准编号：YBH30792025 药品批准文号：国药准字 H20256205 药品批准 ...

每经AI快讯，有投资者在投资者互动平台提问：领导好！公众号《陆玉龙卓越企业研究》今日发文 《北陆药业 13二次探底，考验日线底分型》披露，公司近日公布了一项发明专利"一种布曲钙新型晶型 及其制备方法"。请问：6位发明人都是公司的吗？这个发明专利应用于哪个药品？ 北陆药业（300016.SZ）12月8日在投资者互动平台表示，感谢您的关注。"一种考布曲钙新型晶型及其 制备方法"该项专利申请时发明人均为公司人员，主要应用于制备钆布醇注射液。 （文章来源：每日经济新闻） ...

Group 1 - The core point of the article is that Beilu Pharmaceutical holds a 14.9881% stake in Yiwei Medical, making it the second-largest shareholder [1] Group 2 - Beilu Pharmaceutical responded to investor inquiries on an interactive platform regarding its shareholding [1]